Medicare Part D has historically excluded drugs used for weight loss. For millions of beneficiaries, that made GLP-1 therapy for obesity effectively unaffordable regardless of clinical need.
That changed on July 1, 2026. The Medicare GLP-1 Bridge gives eligible Part D beneficiaries access to certain GLP-1 weight-loss medications for a flat $50 monthly copay, with the drugs furnished outside of the Part D benefit.
If you are on Medicare and have been priced out of these medications, this is the most consequential development available to you — and a striking number of eligible beneficiaries do not know it exists.
There is one detail that catches people out, and it is specific enough to cost you the benefit if you miss it: only the Zepbound KwikPen is covered. Single-dose Zepbound pens and Zepbound vials are not. This article covers what is included, what is not, and how to approach it.
The Programme in Six Facts
It Started July 1, 2026
Medicare.gov states that starting July 1, 2026, Medicare covers certain GLP-1 drugs under this programme for eligible beneficiaries.
The Copay Is a Flat $50 a Month
CMS states eligible beneficiaries have a $50 copay. Against retail pricing frequently exceeding $1,000 a month, that is a difference measured in five figures annually.
Three Products Are Covered
Coverage spans Wegovy (injection and tablet), Zepbound KwikPen, and Foundayo, per Medicare and payer guidance.
Only the Zepbound KwikPen Counts
Medicare.gov states plainly that single-dose Zepbound pens and Zepbound vials are NOT covered. If your prescription is written for a vial, it falls outside the programme.
It Sits Outside the Part D Benefit
CMS states eligible GLP-1 drugs furnished under the Bridge are provided outside of the Part D benefit — which is how the programme works around the historic exclusion of weight-loss drugs.
You Have to Be Eligible and Enrolled
This is for eligible Medicare Part D enrollees, and separate programme enrolment requirements apply. It is not automatic simply because you have Part D.
What Is Covered and What Is Not
The product-level detail here matters more than in most coverage programmes, because the exclusions are unusually specific.
| Product | Covered Under the Bridge? | Notes |
|---|---|---|
| Wegovy injection | Yes | Semaglutide for chronic weight management |
| Wegovy tablet | Yes | The oral semaglutide formulation launched in early 2026 |
| Zepbound KwikPen | Yes | The KwikPen formulation specifically |
| Zepbound single-dose pen | No | Explicitly excluded per Medicare.gov |
| Zepbound vials | No | Explicitly excluded per Medicare.gov |
| Foundayo | Yes | Included per Medicare and payer guidance |
| Ozempic / Mounjaro | Not part of this programme | These carry diabetes indications; Part D coverage for diabetes is a separate question |
| Compounded GLP-1s | No | Compounded preparations are not FDA-approved and are not covered |
Why the KwikPen Distinction Exists and What to Do About It
This is the single most likely way to miss out on the benefit, so it is worth being concrete.
Zepbound is available in more than one presentation. The KwikPen is a multi-dose pen device. Zepbound is also sold as single-dose pens and as vials — the vial format being the one commonly used in self-pay and manufacturer direct channels.
The Bridge covers the KwikPen only. Medicare.gov states directly that the single-dose Zepbound pen and Zepbound vials are not covered, and that your cost for those drugs under this programme does not apply.
The practical consequence: if you are currently getting Zepbound vials through a self-pay channel and you are Bridge-eligible, switching to the covered pathway is not just a matter of telling your pharmacy. Your prescription needs to be written for the KwikPen formulation. Raise this with your prescriber explicitly rather than assuming the pharmacy will substitute.
Check How Your Prescription Is Written
A Zepbound prescription written for vials will not access the $50 Bridge copay. If you are eligible, ask your prescriber to write for the KwikPen formulation specifically.
Wegovy Has Fewer Traps
Both the Wegovy injection and the Wegovy tablet are covered. If you are moving between formulations for tolerability or preference, the Wegovy pathway is more forgiving than the Zepbound one.
CMS Publishes Provider Guidance
CMS maintains an information page for providers on the Medicare GLP-1 Bridge. If your prescriber is unfamiliar with the programme, that is a specific, citable place to point them.
How This Changes the Maths
For an eligible beneficiary, the Bridge does not just reduce cost — it reverses which route is cheapest.
Most of this site is about navigating a market where compounded medication at $99 to $299 a month undercuts brand-name medication costing over $1,000. That comparison holds for most cash-paying patients. It does not hold for a Bridge-eligible Medicare beneficiary.
At $50 a month, FDA-approved Wegovy or Zepbound KwikPen through the Bridge is cheaper than every compounded provider we have reviewed — including the flat-rate leaders at $99. It also carries full FDA review of safety, efficacy and manufacturing quality, which compounded preparations do not, and it carries none of the regulatory uncertainty now surrounding compounded GLP-1s.
If you are eligible for this programme and currently paying a compounded provider, you are very likely paying more for a less regulated product. That is worth checking today rather than at your next renewal.
$50 Beats Every Cash-Pay Option
The cheapest all-inclusive compounded providers we have reviewed sit around $99 a month. The Bridge copay is half that, for approved medication.
And It Is Approved Medication
Wegovy, Zepbound and Foundayo are FDA-approved with full agency review. Compounded preparations are not, and the FDA proposed in April 2026 to exclude these molecules from the 503B bulks list entirely.
Providers Are Building Around It
Found operates a Medicare GLP-1 Bridge pathway helping eligible Part D members access brand-name GLP-1s, and Measured publishes guidance on the programme. If you want help navigating it, those routes exist.
How to Find Out If You Qualify
Eligibility is determined by Medicare and your plan, not by us or by any telehealth provider. These are the places to check.
1. Read the Medicare Publication Directly
Medicare publishes a document on the GLP-1 Bridge covering the $50 monthly cost and what is included. Going to the source avoids the misinformation that surrounds any new coverage programme.
2. Check Medicare.gov Weight Loss Drug Coverage
Medicare.gov maintains a page on weight-loss drug coverage setting out what is covered from July 1, 2026 and the specific Zepbound formulation exclusions.
3. Contact Your Part D Plan
Separate programme enrolment is required for Medicare beneficiaries. Your plan can tell you whether you are eligible and what enrolment involves.
4. Ask Your Prescriber to Check the CMS Provider Page
CMS maintains provider information on the Bridge. If your clinician has not encountered it, that page is the reference — and it matters, because they need to write the prescription correctly.
5. Confirm Before Cancelling Anything
Do not cancel an existing compounded subscription until Bridge access is confirmed and your first covered prescription is filled. Gaps in GLP-1 treatment are worth avoiding.
Our Take
If you are on Medicare Part D and have been priced out of GLP-1 therapy, check this today. A $50 monthly copay for FDA-approved Wegovy, Zepbound KwikPen or Foundayo is better than anything else available to you — better than every compounded provider on price, and better than all of them on regulatory standing.
Get the Zepbound formulation right. The KwikPen is covered; single-dose pens and vials are explicitly not. That distinction is specific enough to cost you the benefit entirely if your prescription is written for the wrong presentation, so raise it with your prescriber directly.
If you are Bridge-eligible and currently paying a compounded provider, you are almost certainly overpaying. Compare your current monthly cost against $50 and act on the difference — but confirm access and fill your first covered prescription before cancelling anything, to avoid a treatment gap.
If you need help navigating it, Found operates a Medicare GLP-1 Bridge pathway and Measured publishes clear guidance on the programme alongside step therapy and prior authorisation. Both are reasonable places to start if the process feels opaque.
Frequently Asked Questions
What is the Medicare GLP-1 Bridge?
It is a programme under which eligible Medicare Part D beneficiaries can access certain GLP-1 weight-loss medications for a flat $50 monthly copay, beginning July 1, 2026. CMS states the eligible drugs are furnished outside of the Part D benefit, which is how the programme works around the historic Part D exclusion of weight-loss drugs.
How much does it cost?
CMS states eligible beneficiaries have a $50 copay. Medicare publishes a document on the programme titled around GLP-1 drugs for $50 a month. Against retail pricing that frequently exceeds $1,000 monthly, the difference over a year is substantial.
Which drugs are covered?
Coverage spans Wegovy (both the injection and the tablet), the Zepbound KwikPen, and Foundayo, per Medicare and payer guidance. Compounded GLP-1s are not covered, as they are not FDA-approved.
Why is Zepbound only covered as a KwikPen?
Medicare.gov states directly that the single-dose Zepbound pen and Zepbound vials are not covered under the programme — the KwikPen formulation is the covered presentation. If you are eligible and currently receiving vials, your prescription needs rewriting for the KwikPen to access the $50 copay.
When did it start?
July 1, 2026. Medicare.gov states that starting on that date, Medicare covers the specified GLP-1 drugs for eligible beneficiaries under the programme.
Am I automatically eligible if I have Part D?
No. Separate programme enrolment is required and eligibility criteria apply. Contact your Part D plan to confirm whether you qualify and what enrolment involves — and check the Medicare publication and Medicare.gov coverage page directly rather than relying on secondary sources.
Is this cheaper than compounded medication?
For an eligible beneficiary, yes, and by a clear margin. The cheapest all-inclusive compounded providers we have reviewed sit around $99 a month; the Bridge copay is $50 for FDA-approved medication. If you are eligible and paying a compounded provider, you are very likely paying more for a less regulated product.
Should I cancel my current provider to switch?
Not until Bridge access is confirmed and your first covered prescription has actually been filled. Gaps in GLP-1 treatment are worth avoiding, and coverage programmes can involve processing time. Confirm first, then cancel.
Disclosure:
This article is based on publicly available information from Medicare.gov including its weight-loss drug coverage page and published Medicare GLP-1 Bridge materials, CMS pages covering the Medicare GLP-1 Bridge and its provider information, and payer and consumer guidance published by Aetna, AARP, GoodRx and eHealth, current as of August 2026. Presidential GLP-1 may receive compensation from some providers featured on this site, which helps us provide free, independent reviews. Eligibility, covered products and programme terms are determined by Medicare and CMS and may change — verify directly with Medicare and your Part D plan rather than relying on this or any secondary source. Nothing here is medical, insurance or legal advice. We do not sell, dispense, or ship medication.
⚕ Medical Disclaimer:
This article is for informational purposes only and is not medical advice. Prescription weight-management medications carry serious risks and contraindications; GLP-1 receptor agonists carry a boxed warning for thyroid C-cell tumors. Only a licensed clinician who knows your medical history can determine whether any weight-management medication is appropriate for you. See our full medical disclaimer.
Related Guides & Articles
Zeus Health
GLP-1 care built into primary care, with brand-name medication from $25/month with insurance.
GLP-1 Insurance, HSA and FSA Guide
The full picture on coverage and pre-tax payment routes.
Measured Review
Insurance-first provider publishing clear guidance on the Bridge and prior authorisation.
Best GLP-1 Providers With Insurance
Where your plan benefit goes furthest.
The Five GLP-1 Pricing Models
How insurance-first compares against cash-pay structures.
Compare All GLP-1 Providers
Read our independent reviews of every provider we cover
View All Reviews →